Form 4: BioXcel Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Susan E. Atkins, a Director of BioXcel Therapeutics, Inc., received 17,000 shares of common stock on August 12, 2026.
Summary
- Grant/award: acquired 17,000 Stock Option (Right to Buy) on August 12, 2026; holds 17,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Susan E. Atkins — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Grant/award | Stock Option (Right to Buy) | 17,000 | — | — | 17,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Grant/award (17,000 shares) |
Keywords
insider transaction, Form 4, BTAI, BioXcel Therapeutics, Inc., neutral, Susan E. Atkins
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.